Meet One-on-One with…Thomas, McNerney & Partners

Dec 4 2012

Congratulations! You have been approved to attend a one-on-one meeting with TMP. To secure your time slot please register by choosing the desired ticket above. After receiving confirmation of your registration you will be notified of your meeting time slot.


10:30am | Registration & Networking   
11:00am | Presentation & Q&A  
11:30pm | Lunch & Networking
12:30pm | Optional Tours of Janssen Labs  
12:30pm | One-on-one Meetings

Program Overview
Thomas, McNerney & Partners is a national venture firm investing in life science and medical technology companies at all stages of development. Three members of the firm’s team will be in attendance on December 4 to give an overview presentation on their key areas of interest, background on their current portfolio and best practices when starting down the road of venture capital investment. Following the presentation, don’t miss this opportunity to introduce yourself to the firm during the event’s networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Thomas, McNerney will provide a forum to further discuss your company with the firm’s team leaders.

With investment interests in the pharmaceutical, medical device, biotechnology and diagnostic sectors, leaders from all areas of the life science industry are encouraged to apply today to meet with Thomas, McNerney!

Company Representatives in Attendance
Pratik Shah | Partner, Thomas, McNerney & Partners
Jason Brown | Principal, Thomas, McNerney & Partners
Justin Chakma | Analyst, Thomas, McNerney & Partners

Thomas, McNerney & Partners Biographies
Pratik Shah | Partner, Thomas, McNerney & Partners
Pratik joined Thomas, McNerney & Partners in 2004 and is currently a board member of Auspex Pharmaceuticals, Inc., Cebix Incorporated, CNS Therapeutics, Inc., Ocera Therapeutics, Inc. and SGB, Inc.  Prior to joining the firm, he was the Chief Business Officer and co-founder of Kalypsys, Inc., a biopharmaceutical company focused on the discovery and clinical development of new medicines for cancer, inflammation and metabolic disease using its proprietary automation technologies. Before co-founding Kalypsys, Pratik was at McKinsey & Company where he focused on biotechnology and venture capital projects. He was formerly co-founder and VP of Operations at NephRx Corporation, a start-up company focused on the discovery of therapeutic proteins for renal disease. Pratik holds a B.S. in Biological Sciences from the University of California at Irvine and both a Ph.D. in Biochemistry & Molecular Biology and an M.B.A. from the University of Chicago.

Jason Brown | Principal, Thomas, McNerney & Partners
Jason joined Thomas, McNerney & Partners in 2007 after spending four years as a member of the investment team at Forward Ventures, where he played an active role in Forward-led rounds of investment totaling over $50 million. Prior to joining Forward, Jason conducted research in antimicrobial drug discovery and bacterial genomics as a postdoctoral fellow in Infectious Diseases at Johnson & Johnson Pharmaceutical Research and Development. He is currently a board member of NeuroTherapeutics Pharma, Inc. and Tioga Pharmaceuticals, Inc. Jason earned a Ph.D. in Biology at the University of California, San Diego, where he was a National Science Foundation Fellow, and a B.S. in Molecular Biology and Biochemistry from Purdue University.

Justin Chakma | Analyst, Thomas, McNerney & Partners
Justin joined Thomas, McNerney & Partners in 2012. His prior experience includes positions at Leerink Swann and MaRS Innovation. Justin has conducted research in support of the Bill and Melinda Gates Foundation and has published multiple articles on emerging market innovation in Nature Biotechnology. He received his Hon. B.A. with highest distinction in economics and neuroscience from the University of Toronto.